201 related articles for article (PubMed ID: 25537514)
21. Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.
Moes-Sosnowska J; Rzepecka IK; Chodzynska J; Dansonka-Mieszkowska A; Szafron LM; Balabas A; Lotocka R; Sobiczewski P; Kupryjanczyk J
Cancer Biol Ther; 2019; 20(6):843-854. PubMed ID: 30822218
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases.
Yazici H; Glendon G; Yazici H; Burnie SJ; Saip P; Buyru F; Bengisu E; Andrulis IL; Dalay N; Ozcelik H
Hum Mutat; 2002 Jul; 20(1):28-34. PubMed ID: 12112655
[TBL] [Abstract][Full Text] [Related]
23. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ;
Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
Kwa M; Edwards S; Downey A; Reich E; Wallach R; Curtin J; Muggia F
Ann Surg Oncol; 2014 May; 21(5):1468-73. PubMed ID: 24081797
[TBL] [Abstract][Full Text] [Related]
25. Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
Machackova E; Damborsky J; Valik D; Foretova L
Hum Mutat; 2001 Dec; 18(6):545. PubMed ID: 11748848
[TBL] [Abstract][Full Text] [Related]
26. Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.
Ellberg C; Jernström H; Broberg P; Borg Å; Olsson H
Genes Chromosomes Cancer; 2015 Jan; 54(1):39-50. PubMed ID: 25251729
[TBL] [Abstract][Full Text] [Related]
27. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA
Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105
[TBL] [Abstract][Full Text] [Related]
29. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
30. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
[TBL] [Abstract][Full Text] [Related]
31. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
[TBL] [Abstract][Full Text] [Related]
32. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes.
Akbari MR; Zhang S; Fan I; Royer R; Li S; Risch H; McLaughlin J; Rosen B; Sun P; Narod SA
J Med Genet; 2011 Nov; 48(11):783-6. PubMed ID: 21965345
[TBL] [Abstract][Full Text] [Related]
34. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
35. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.
Tan DS; Yap TA; Hutka M; Roxburgh P; Ang J; Banerjee S; Grzybowska E; Gourley C; Gore ME; Kaye SB
Eur J Cancer; 2013 Apr; 49(6):1246-53. PubMed ID: 23265709
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA in breast cancer: The association with BRCA1/2.
Petrovic N; Davidovic R; Bajic V; Obradovic M; Isenovic RE
Cancer Biomark; 2017; 19(2):119-128. PubMed ID: 28128741
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
[TBL] [Abstract][Full Text] [Related]
38. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.
Kang HC; Kim IJ; Park JH; Kwon HJ; Won YJ; Heo SC; Lee SY; Kim KH; Shin Y; Noh DY; Yang DH; Choe KJ; Lee BH; King SB; Park JG
Hum Mutat; 2002 Sep; 20(3):235. PubMed ID: 12204006
[TBL] [Abstract][Full Text] [Related]
39. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
40. Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles.
Elias K; Smyczynska U; Stawiski K; Nowicka Z; Webber J; Kaplan J; Landen C; Lubinski J; Mukhopadhyay A; Chakraborty D; Connolly DC; Symecko H; Domchek SM; Garber JE; Konstantinopoulos P; Fendler W; Chowdhury D
Nat Commun; 2023 Jun; 14(1):3350. PubMed ID: 37291133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
